Pharmacology of orthostatic hypotension in Parkinson's disease: from pathophysiology to management.
Identifieur interne : 000E99 ( PubMed/Checkpoint ); précédent : 000E98; suivant : 000F00Pharmacology of orthostatic hypotension in Parkinson's disease: from pathophysiology to management.
Auteurs : Atul Pathak [France] ; Jean-Michel SenardSource :
- Expert review of cardiovascular therapy [ 1477-9072 ] ; 2004.
English descriptors
- KwdEn :
- Antiparkinson Agents (adverse effects), Autonomic Nervous System Diseases (drug therapy), Autonomic Nervous System Diseases (epidemiology), Autonomic Nervous System Diseases (physiopathology), Blood Volume (drug effects), Efferent Pathways (drug effects), Efferent Pathways (physiopathology), Humans, Hypotension, Orthostatic (chemically induced), Hypotension, Orthostatic (drug therapy), Hypotension, Orthostatic (epidemiology), Hypotension, Orthostatic (physiopathology), Parkinson Disease (drug therapy), Parkinson Disease (epidemiology), Parkinson Disease (physiopathology), Postprandial Period (drug effects), Vasoconstrictor Agents (therapeutic use).
- MESH :
- chemical , adverse effects : Antiparkinson Agents.
- chemically induced : Hypotension, Orthostatic.
- drug effects : Blood Volume, Efferent Pathways, Postprandial Period.
- drug therapy : Autonomic Nervous System Diseases, Hypotension, Orthostatic, Parkinson Disease.
- epidemiology : Autonomic Nervous System Diseases, Hypotension, Orthostatic, Parkinson Disease.
- physiopathology : Autonomic Nervous System Diseases, Efferent Pathways, Hypotension, Orthostatic, Parkinson Disease.
- chemical , therapeutic use : Vasoconstrictor Agents.
- Humans.
Abstract
Orthostatic hypotension is highly prevalent in the elderly, and affects up to 20% of patients with Parkinson's disease. Pharmacological approaches help to demonstrate that Parkinson's disease is a primary autonomic failure with involvement of the peripheral autonomic nervous system as shown by decreased [(123)I] meta-iodobenzylguanidine cardiac uptake and preserved growth hormone response to clonidine. No specific clinical trial has evaluated efficacy of antihypotensive drugs in Parkinson's disease. End point of treatment should be a reduction in postural symptoms. Midodrine (Proamatin), Roberts Pharmaceutical), a vasoconstrictor and fludrocortisone (Florinef), Bristol-Myers Squibb), a volume expander are first choice drugs. No data are available on their effects on orthostatic hypotension-related morbidity. The usefulness of other drugs remains to be demonstrated. This review will highlight the importance of nonpharmacological measures in the management of orthostatic hypotension in Parkinson's disease.
DOI: 10.1586/14779072.2.3.393
PubMed: 15151485
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:15151485Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pharmacology of orthostatic hypotension in Parkinson's disease: from pathophysiology to management.</title><author><name sortKey="Pathak, Atul" sort="Pathak, Atul" uniqKey="Pathak A" first="Atul" last="Pathak">Atul Pathak</name><affiliation wicri:level="3"><nlm:affiliation>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U586, 37 allées Jules Guesde, 31073 Toulouse cedex, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U586, 37 allées Jules Guesde, 31073 Toulouse cedex</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Senard, Jean Michel" sort="Senard, Jean Michel" uniqKey="Senard J" first="Jean-Michel" last="Senard">Jean-Michel Senard</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:15151485</idno><idno type="pmid">15151485</idno><idno type="doi">10.1586/14779072.2.3.393</idno><idno type="wicri:Area/PubMed/Corpus">001020</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001020</idno><idno type="wicri:Area/PubMed/Curation">000F79</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000F79</idno><idno type="wicri:Area/PubMed/Checkpoint">000F79</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000F79</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Pharmacology of orthostatic hypotension in Parkinson's disease: from pathophysiology to management.</title><author><name sortKey="Pathak, Atul" sort="Pathak, Atul" uniqKey="Pathak A" first="Atul" last="Pathak">Atul Pathak</name><affiliation wicri:level="3"><nlm:affiliation>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U586, 37 allées Jules Guesde, 31073 Toulouse cedex, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U586, 37 allées Jules Guesde, 31073 Toulouse cedex</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Senard, Jean Michel" sort="Senard, Jean Michel" uniqKey="Senard J" first="Jean-Michel" last="Senard">Jean-Michel Senard</name></author></analytic><series><title level="j">Expert review of cardiovascular therapy</title><idno type="ISSN">1477-9072</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (adverse effects)</term><term>Autonomic Nervous System Diseases (drug therapy)</term><term>Autonomic Nervous System Diseases (epidemiology)</term><term>Autonomic Nervous System Diseases (physiopathology)</term><term>Blood Volume (drug effects)</term><term>Efferent Pathways (drug effects)</term><term>Efferent Pathways (physiopathology)</term><term>Humans</term><term>Hypotension, Orthostatic (chemically induced)</term><term>Hypotension, Orthostatic (drug therapy)</term><term>Hypotension, Orthostatic (epidemiology)</term><term>Hypotension, Orthostatic (physiopathology)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (epidemiology)</term><term>Parkinson Disease (physiopathology)</term><term>Postprandial Period (drug effects)</term><term>Vasoconstrictor Agents (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Hypotension, Orthostatic</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Blood Volume</term><term>Efferent Pathways</term><term>Postprandial Period</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Autonomic Nervous System Diseases</term><term>Hypotension, Orthostatic</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Autonomic Nervous System Diseases</term><term>Hypotension, Orthostatic</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Autonomic Nervous System Diseases</term><term>Efferent Pathways</term><term>Hypotension, Orthostatic</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Vasoconstrictor Agents</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Orthostatic hypotension is highly prevalent in the elderly, and affects up to 20% of patients with Parkinson's disease. Pharmacological approaches help to demonstrate that Parkinson's disease is a primary autonomic failure with involvement of the peripheral autonomic nervous system as shown by decreased [(123)I] meta-iodobenzylguanidine cardiac uptake and preserved growth hormone response to clonidine. No specific clinical trial has evaluated efficacy of antihypotensive drugs in Parkinson's disease. End point of treatment should be a reduction in postural symptoms. Midodrine (Proamatin), Roberts Pharmaceutical), a vasoconstrictor and fludrocortisone (Florinef), Bristol-Myers Squibb), a volume expander are first choice drugs. No data are available on their effects on orthostatic hypotension-related morbidity. The usefulness of other drugs remains to be demonstrated. This review will highlight the importance of nonpharmacological measures in the management of orthostatic hypotension in Parkinson's disease.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15151485</PMID><DateCreated><Year>2004</Year><Month>05</Month><Day>20</Day></DateCreated><DateCompleted><Year>2004</Year><Month>11</Month><Day>08</Day></DateCompleted><DateRevised><Year>2005</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1477-9072</ISSN><JournalIssue CitedMedium="Print"><Volume>2</Volume><Issue>3</Issue><PubDate><Year>2004</Year><Month>May</Month></PubDate></JournalIssue><Title>Expert review of cardiovascular therapy</Title><ISOAbbreviation>Expert Rev Cardiovasc Ther</ISOAbbreviation></Journal><ArticleTitle>Pharmacology of orthostatic hypotension in Parkinson's disease: from pathophysiology to management.</ArticleTitle><Pagination><MedlinePgn>393-403</MedlinePgn></Pagination><Abstract><AbstractText>Orthostatic hypotension is highly prevalent in the elderly, and affects up to 20% of patients with Parkinson's disease. Pharmacological approaches help to demonstrate that Parkinson's disease is a primary autonomic failure with involvement of the peripheral autonomic nervous system as shown by decreased [(123)I] meta-iodobenzylguanidine cardiac uptake and preserved growth hormone response to clonidine. No specific clinical trial has evaluated efficacy of antihypotensive drugs in Parkinson's disease. End point of treatment should be a reduction in postural symptoms. Midodrine (Proamatin), Roberts Pharmaceutical), a vasoconstrictor and fludrocortisone (Florinef), Bristol-Myers Squibb), a volume expander are first choice drugs. No data are available on their effects on orthostatic hypotension-related morbidity. The usefulness of other drugs remains to be demonstrated. This review will highlight the importance of nonpharmacological measures in the management of orthostatic hypotension in Parkinson's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pathak</LastName><ForeName>Atul</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U586, 37 allées Jules Guesde, 31073 Toulouse cedex, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Senard</LastName><ForeName>Jean-Michel</ForeName><Initials>JM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Cardiovasc Ther</MedlineTA><NlmUniqueID>101182328</NlmUniqueID><ISSNLinking>1477-9072</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014662">Vasoconstrictor Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001342" MajorTopicYN="N">Autonomic Nervous System Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001810" MajorTopicYN="N">Blood Volume</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004525" MajorTopicYN="N">Efferent Pathways</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007024" MajorTopicYN="N">Hypotension, Orthostatic</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019518" MajorTopicYN="N">Postprandial Period</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014662" MajorTopicYN="N">Vasoconstrictor Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>72</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>5</Month><Day>21</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>11</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>5</Month><Day>21</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15151485</ArticleId><ArticleId IdType="pii">ERC020309</ArticleId><ArticleId IdType="doi">10.1586/14779072.2.3.393</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Midi-Pyrénées</li><li>Occitanie (région administrative)</li></region><settlement><li>Toulouse</li></settlement></list><tree><noCountry><name sortKey="Senard, Jean Michel" sort="Senard, Jean Michel" uniqKey="Senard J" first="Jean-Michel" last="Senard">Jean-Michel Senard</name></noCountry><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Pathak, Atul" sort="Pathak, Atul" uniqKey="Pathak A" first="Atul" last="Pathak">Atul Pathak</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E99 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000E99 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:15151485
|texte= Pharmacology of orthostatic hypotension in Parkinson's disease: from pathophysiology to management.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:15151485" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |